Bio-Rad Laboratories Inc. Class B

788.75-29.85-3.65%Vol 3001Y Perf 64.25%
Sep 13th, 2021 18:40 DELAYED
BID798.15 ASK800.90
Open814.34 Previous Close818.60
Pre-Market- After-Market-
 - -%  - -
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★★     69.47
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     84.04
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
91.18 
Earnings Rating
Buy
Market Cap23.48B 
Earnings Date
4th Nov 2021
Alpha0.02 Standard Deviation0.07
Beta0.77 

Today's Price Range

788.75814.34

52W Range

480.20818.60

5 Year PE Ratio Range

5.60275.30

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
0.00%
1 Month
3.40%
3 Months
36.09%
6 Months
36.14%
1 Year
64.25%
3 Years
164.97%
5 Years
390.73%
10 Years
-

TickerPriceChg.Chg.%
BIO.B788.75-29.8500-3.65
AAPL146.971.12000.77
GOOG2 842.0423.27000.83
MSFT300.061.48000.50
XOM57.091.88003.41
WFC48.060.98002.08
JNJ165.641.71001.04
FB346.673.46001.01
GE103.715.17005.25
JPM161.575.66003.63
Financial StrengthValueIndustryS&P 500US Markets
2.70
3.90
0.01
0.02
467.10
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
56.60
181.50
186.30
52.70
84.36
RevenueValueIndustryS&P 500US Markets
2.88B
568.15
5.80
5.45
Earnings HistoryEstimateReportedSurprise %
Q02 2021-3.54-
Q01 2021-5.21-
Q04 2020-4.01-
Q03 2020-3.00-
Q02 2020-1.61-
Q01 2020-1.91-
Q04 2019-2.32-
Q03 2019-1.61-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date4th Nov 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume300
Shares Outstanding29.77M
Shares Float164.22K
Trades Count33
Dollar Volume30.12K
Avg. Volume226
Avg. Weekly Volume640
Avg. Monthly Volume405
Avg. Quarterly Volume567

Bio-Rad Laboratories Inc. Class B (NYSE: BIO.B) stock closed at 788.75 per share at the end of the most recent trading day (a -3.65% change compared to the prior day closing price) with a volume of 300.0000 shares and market capitalization of 23.48B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 8000 people. Bio-Rad Laboratories Inc. Class B CEO is Norman Schwartz.

The one-year performance of Bio-Rad Laboratories Inc. Class B stock is 64.25%, while year-to-date (YTD) performance is 37.38%. BIO.B stock has a five-year performance of 390.73%. Its 52-week range is between 480.2 and 818.6, which gives BIO.B stock a 52-week price range ratio of 91.18%

Bio-Rad Laboratories Inc. Class B currently has a PE ratio of 5.90, a price-to-book (PB) ratio of 2.03, a price-to-sale (PS) ratio of 1.39, a price to cashflow ratio of 34.60, a PEG ratio of 2.32, a ROA of 31.39%, a ROC of 40.75% and a ROE of 41.80%. The company’s profit margin is 84.36%, its EBITDA margin is 186.30%, and its revenue ttm is $2.88 Billion , which makes it $568.15 revenue per share.

Of the last four earnings reports from Bio-Rad Laboratories Inc. Class B, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Bio-Rad Laboratories Inc. Class B’s next earnings report date is 04th Nov 2021.

The consensus rating of Wall Street analysts for Bio-Rad Laboratories Inc. Class B is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Bio-Rad Laboratories Inc. Class B stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Bio-Rad Laboratories Inc. Class B has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Bio-Rad Laboratories Inc. Class B has a Buy technical analysis rating based on Technical Indicators (ADX : 83.45, ATR14 : 13.62, CCI20 : 44.24, Chaikin Money Flow : 0.58, MACD : 14.52, Money Flow Index : 25.85, ROC : 3.40, RSI : 43.77, STOCH (14,3) : 47.95, STOCH RSI : 1.00, UO : 10.28, Williams %R : -52.05), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Bio-Rad Laboratories Inc. Class B in the last 12-months were: Ajit Ramalingam (Option Excercise at a value of $0), Andrew J. Last (Option Excercise at a value of $598 480), Andrew J. Last (Sold 2 000 shares of value $1 626 203 ), Annette Tumolo (Option Excercise at a value of $191 184), Annette Tumolo (Sold 1 800 shares of value $1 244 413 ), Dara Wright (Option Excercise at a value of $0), Ilan Daskal (Option Excercise at a value of $716 898), Ilan Daskal (Sold 3 110 shares of value $2 397 778 ), Michael Crowley (Option Excercise at a value of $418 680), Michael Crowley (Sold 3 374 shares of value $2 481 966 ), Norman Schwartz (Option Excercise at a value of $3 702 220), Timothy S. Ernst (Option Excercise at a value of $63 728), Timothy S. Ernst (Sold 1 446 shares of value $965 649 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Bio-Rad Laboratories Inc. Class B

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (60% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the United States (40% of 2019 sales), Europe (33%), and Asia (22%), with Canada and Latin America accounting for the bulk of the remaining 5%. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

CEO: Norman Schwartz

Telephone: +1 510 724-7000

Address: 1000 Alfred Nobel Drive, Hercules 94547, CA, US

Number of employees: 8 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

57%43%

Bearish Bullish

69%31%

News

Stocktwits